TL;DR — Sulforaphane covalently modifies KEAP1, stabilizing NRF2A protein that turns on 200+ antioxidant and detox genes when activated. Full glossary → and upregulating 200+ cytoprotective genes. Tier A mechanistic and human cell data; 10–30 mg active SFN AM before GlyNAC in the NRF2 triad. Retest hs-CRP and GSH at 12 weeks.
What sulforaphane does (and why it matters)
Cells face constant electrophilic and oxidative stressAn imbalance between reactive oxygen species (free radicals) produced by metabolism and the antioxidant systems that neutralize them. Full glossary →. NRF2 is the master transcription factor for phase-II detox, antioxidant enzymes, proteasome subunits, and heat shock proteins — but in baseline state, KEAP1 holds NRF2 in the cytoplasm for degradation.
Sulforaphane (an isothiocyanate from cruciferous vegetables) modifies KEAP1 cysteine residues, releasing NRF2 for nuclear translocation. One activation event can induce a broad ARE gene battery (NQO1, HO-1, GCLC, GST).
Primary hallmarks targeted: Genomic instability · Chronic inflammation · Loss of proteostasis · Dysbiosis (gut barrier)
PMID 38772511: sulforaphane modifies KEAP1 cysteine residues, stabilizing NRF2 for nuclear translocation. Human airway epithelial studies confirm dose-dependent NRF2 target gene induction and downstream NF-κB suppression.
Mechanism — gene switch, not antioxidant pill
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| NRF2 → ARE genes | Phase II detox + GSH synthesis enzymes | Genomic instability |
| NRF2 → NF-κB brake | Direct inflammatory transcription suppression | Chronic inflammation |
| Proteasome upregulation | Clears damaged proteins | Proteostasis |
| Gut epithelial NRF2 | Barrier strengthening (preclinical) | Dysbiosis |
Sulforaphane does not donate electrons like vitamin C — it changes gene expression. That is why pairing with GlyNAC substrate (GSH precursors) outperforms either alone in the TNiC NRF2 architecture.
When sulforaphane is worth your money
Sulforaphane earns a stack slot when two or more apply:
- hs-CRP above 1.0 mg/L on two tests 8+ weeks apart
- GSH below 5.0 μmol/L or high oxidative lifestyle load
- You're running GlyNAC and need the NRF2 gene induction leg
- Gut barrier symptoms + elevated CRP (adjunct to fiber protocol)
Skip or defer if you have not run GlyNAC 4+ weeks, sleep is under 6 hours, or you're on high-dose immunosuppressants without physician clearance.
Evidence summary
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Fahey / Dinkova-Kostova | Mechanistic | Cell + human tissue | Acute | KEAP1 modification, NRF2 nuclear translocation | A |
| Riedl et al. airway | Human ex vivo | Epithelial | Hours | Dose-dependent ARE gene induction | A |
| NRF2-NF-κB crosstalk | Review/mechanistic | — | — | Inflammatory suppression downstream | A |
← Swipe for more columns →
Consensus: Tier A for NRF2 activation mechanism and human cell/tissue confirmation. Tier B for standalone longevity endpoints — human trials focus on biomarker and pathway markers, not mortality.
Where sulforaphane disappoints
- Product roulette. Most of the disappointment traces to the label: "glucoraphanin" capsules with no active myrosinase deliver a fraction of the sulforaphane a sprout extract does. You can take a full dose and absorb almost nothing. - Individual conversion varies enormously. How much sulforaphane you actually generate depends on your gut microbiome and enzyme status — two people on the same product can differ several-fold. - No acute "feel." It changes gene expression over hours to days, not electron-donation you notice. People expecting an antioxidant "kick" conclude it isn't working when the readout is simply CRP and GSH over weeks.
Should you start sulforaphane?
Already on GlyNAC 600/600 AM for 4+ weeks?
node | hs-CRP still above 1.0 OR GSH below 5.0?
Add sulforaphane 10–30 mg AM → full triad week 8 with R-ALA
Maintain GlyNAC; retest labs at week 12 before adding
Start GlyNAC first per GlyNAC guide → sulforaphane week 4–8
Active autoimmune flare on immunosuppressants — rheumatologist coordination before NRF2 intensification
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
What would change this grade. The A reflects a well-established mechanism confirmed in human cells and tissue, not proven longevity outcomes. It would earn an outcome-level grade with adequately powered RCTs showing disease or aging endpoints move — not just NRF2 target genes and CRP. It would fall if the reliable biomarker shifts turn out not to track any meaningful clinical benefit.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 10–35 mg glucoraphanin or 10–30 mg active SFN | Broccoli sprout extract preferred |
| Timing | AM, 15–30 min before or after GlyNAC | NRF2 triad morning block |
| Form | Myrosinase-active sprout extract | Critical for glucoraphanin conversion |
| Duration | Minimum 12 weeks | Pair with GSH retest at week 12 |
Week-one compliance checklist
- [ ] Confirm myrosinase-active label (not glucoraphanin-only without enzyme)
- [ ] Set AM alarm 15 min before GlyNAC dose
- [ ] Log baseline hs-CRP and GSH if available
- [ ] Schedule week-12 lab draw before starting
- [ ] Read NRF2 Triad choreography
Add sulforaphane to your stack
NRF2 triad synergyWhen two compounds together produce greater effect than either alone. Full glossary → score peaks when GlyNAC + sulforaphane + R-ALA legs are all enabled.
Open Stack ArchitectMonitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| hs-CRP | <1.0 mg/L | Baseline, 12 wk | Audit alcohol, visceral fat, sleep |
| GSH | 5.0–8.5 μmol/L | 12–24 wk | Continue triad; verify GlyNAC compliance |
| 8-OHdG | Trending down | 6 mo | Oxidative DNA damage proxy |
| Subjective inflammation | ≤3/10 | Weekly | Joint stiffness, brain fog log |
← Swipe for more columns →
hs-CRP (mg/L)
1.5–3.0
GSH (μmol/L)
3.0–4.5
Inflammation score (1–10)
6–8
hs-CRP (mg/L)
<1.0
GSH (μmol/L)
5.0–8.5
Inflammation score (1–10)
≤3
Track biomarkers
Log hs-CRP and GSH at baseline and week 12 — the NRF2 triad primary endpoints.
Open Labs hubSafety, red flags, and contraindications
- Generally well tolerated at food-equivalent doses; mild GI upset possible on empty stomach
- Broccoli sprout extracts — verify third-party testing for heavy metals
Do not self-start without clearance
- Thyroid disease on levothyroxine — cruciferous compounds may affect iodine uptake at very high doses; monitor TSH
- Active autoimmune flare — NRF2 modulation is adjunct only, not replacement for immunosuppression
- Warfarin or anticoagulants — cruciferous vegetable consistency matters; physician awareness
Who should skip sulforaphane
- Anyone buying a glucoraphanin-only capsule with no myrosinase — you'll pay for conversion that doesn't happen; fix the product first. - Thyroid disease at very high (supra-food) doses without TSH monitoring — cruciferous compounds can affect iodine uptake. - An active autoimmune flare — NRF2 modulation is an adjunct, never a substitute for prescribed immunosuppression.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| GlyNAC | GSH substrate before NRF2 gene induction | NRF2 Triad |
| R-ALA | Regenerates antioxidant network | NRF2 Triad |
| Broccoli sprouts (food) | Dietary glucoraphanin + myrosinase | Nutrition |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Heat / cooking the source | Destroys myrosinase, so glucoraphanin never converts to sulforaphane | Use a myrosinase-active extract or raw sprouts; don't rely on cooked broccoli |
| High-dose direct antioxidants around dosing | Blunting the mild oxidative signal can dampen NRF2 induction (same debate as with exercise) | Don't megadose vitamin C/E at the same time; let the gene switch fire |
| Duplicate NRF2 activators stacked blindly | Overlapping ceiling on the same pathway — more isn't proportionally more | Anchor to the GlyNAC substrate leg rather than piling on activators |
Personal results template
My sulforaphane results log
| Date | Week | Dose | hs-CRP | GSH | Inflammation (1–10) | Stack partners | Notes |
|---|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | GlyNAC only | Baseline |
| YYYY-MM-DD | 4 | 15 mg | — | — | — | + SFN | Ramp |
| YYYY-MM-DD | 12 | 25 mg | — | — | — | Full triad | Primary endpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: hs-CRP ↓30%+ and inflammation score ≤3 - Plateau: Audit lifestyle (alcohol, sleep, visceral fat) before dose escalation - Adverse: GI distress, thyroid symptoms → reduce dose, physician consult
Log your experiment
Track NRF2 triad compliance and lab trajectory in your longitudinal journal.
Personal journeyReferences
- See PMID registry. Sulforaphane upregulates NRF2 and NQO1 in CKD patients. Free Radic Biol Med (2024). PMID 38772511
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.